Patent Law Weblog
recent posts
- Moderna Settles Patent Litigation with Arbutus et al.
- USPTO and DOJ Statement of Interest in Collision Communications: Another Thumb on the Scale in Favor of NPE Patent Plaintiffs
- Oasis Tooling, Inc. v. Siemens Industry Software Inc. (Fed. Cir. 2026)
- Why AI Will Not Take Over the World
- BioNTech Sues Moderna over mRNA Vaccine Technology
about
Category: Biotech/Pharma News
-
By Kevin E. Noonan — Before starting the Iraq war, the Bush Administration action with the most long-lasting effect and significance was its decision, in August 2001, to restrict Federal funding of human embryonic stem cell research. The government refused to fund research on any stem cell line not existing at the time…
-
By Christopher P. Singer — Angiotech® announced in a March 15, 2007 press release that the European Patent Office’s Technical Board of Appeal denied Conor Medsystems Inc.’s and Sahajanand Medical Technologies Pvt. Ltd.’s request to intervene and appeal a prior ruling by the Opposition Division of the EPO regarding Angiotech’s "Hunter" patent (EP…
-
By Jason Derry — Abbott Laboratories has announced that it will no longer launch new medicines in Thailand. In addition, Abbott has decided to withdraw its current applications for medicines in Thailand. The decision is based on Thailand’s recent decision to issue compulsory licenses for Abbott’s AIDS drug Kaletra, and the failure to…
-
By Mark Chael Novartis announced today that the U.S. Food and Drug Administration approved the use of Tekturna® (aliskiren) for the treatment of high blood pressure as a single therapy or in combination with other high blood pressure medications. Apparently, the FDA had previously indicated that it would need more time to review…
-
By Kevin E. Noonan A state appeals court in San Francisco upheld the California Institute for Regenerative Medicine (CIRM), the result of passage (by a referendum vote of 59% of California voters) of Proposition 71 in 2004. The CIRM and California’s legal capacity to fund the Institute under Proposition 71 were challenged by…
-
By Kevin E. Noonan Five years ago, reports from the University of Minnesota promised to reconcile the budding science of human stem cell biology with the restrictive regulations the Bush administration had imposed on federally funded embryonic stem cell research. These reports indicated that adult stem cells, specifically hematopoietic stem cells that are…
-
By Kevin E. Noonan DNA has a unique status among biological molecules, being both a chemical and information comprising the nucleotide sequence that encodes the amino acid sequence of a gene’s cognate protein. In a recent article in Science, Michael Gottesman and his colleagues at the National Institutes of Health have demonstrated that…
-
By Kevin E. Noonan Earlier this week, the National Eye Institutes (NEI) of the National Institutes of Health announced that it would conduct a study comparing the effectiveness of two Genentech drugs, Lucentis® and Avastin®, for the treatment of age-related macular degeneration (AMD). This was not good news for Genentech, because although treating…
-
By Kevin E. Noonan The news keeps getting worse for Genentech. On the heels of the announcement that the National Institutes of Health would fund a study comparing the efficacy of Lucentis® and Avastin® (see "Retinal Specialist on the Avastin®/Lucentis® Controversy"), Genentech disclosed the results of an Avastin® study done by its parent…
-
By Kevin E. Noonan The U.S. National Institutes of Health (NIH) announced Wednesday that it had assembled a database of the entire genomic complement of 2,000 human and avian influenza strains that are publicly available from the National Institute of Allergy and Infectious Diseases (NIAID). The information in this database represents flu samples…
Patent Docs 